EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis

Mishal Qubad iD, Gabriele Dupont iD, Martina Hahn iD, Simon S Martin iD, Valentina Puntmann iD, Eike Nagel iD, Andreas Reif iD, Robert A Bittner iD

CNS Drugs · 2024-09 · 38 (9) · 671-696

DOI: 10.1007/s40263-024-01100-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CNS Drugs, online erschienen am 01.07.2024. Verfasst von Mishal Qubad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University Frankfurt, University Hospital, Frankfurt, Germany. mishal.quba…. Hauptthemen laut MEDLINE: Myocarditis, Clozapine, Schizophrenia, Antipsychotic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 276 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johann Wolfgang Goethe-Universität, Frankfurt am Main.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisClozapineSchizophreniaAntipsychotic AgentsHumansRisk Factors

Substanzen

ClozapineAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University Frankfurt, University Hospital, Frankfurt, Germany. mishal.qubad@med.uni-frankfurt.de.
  • Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University Frankfurt, University Hospital, Frankfurt, Germany.
  • Department of Mental Health, Varisano Hospital Frankfurt Hoechst, Frankfurt, Germany.
  • Department of Radiology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany.
  • Department of Cardiology, Institute for Experimental and Translational Cardiovascular Imaging, Goethe University Frankfurt, University Hospital, Frankfurt, Germany.
  • Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University Frankfurt, University Hospital, Frankfurt, Germany. robert.bittner@med.uni-frankfurt.de.

ORCID-Profile: Mishal Qubad, Gabriele Dupont, Martina Hahn, Simon S Martin, Valentina Puntmann, Eike Nagel, Andreas Reif, Robert A Bittner

Förderung

  • Johann Wolfgang Goethe-Universität, Frankfurt am Main

Zitieren

APA

Qubad, M., Dupont, G., Hahn, M., Martin, S. S., Puntmann, V., Nagel, E., Reif, A., & Bittner, R. A. (2024). When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis. CNS Drugs, 38(9), 671-696. https://doi.org/10.1007/s40263-024-01100-4

Vancouver

Qubad M, Dupont G, Hahn M, Martin SS, Puntmann V, Nagel E, et al. When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis. CNS Drugs. 2024;38(9):671-696. doi:10.1007/s40263-024-01100-4

BibTeX
@article{Qubad2024,
  author = {Qubad, Mishal and Dupont, Gabriele and Hahn, Martina and Martin, Simon S and Puntmann, Valentina and Nagel, Eike and Reif, Andreas and Bittner, Robert A},
  title = {When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis},
  journal = {CNS Drugs},
  year = {2024},
  volume = {38},
  number = {9},
  pages = {671--696},
  doi = {10.1007/s40263-024-01100-4}
}
Kostenlos starten →